ArticleBMC cancer2025
A comparative study on prognostic differences between men and women with non-small cell lung cancer across different antitumor treatment modalities.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate potential prognostic differences between male and female patients with non-small cell lung cancer under various antitumor treatment modalities, as well as to analyze potential factors influencing these differences.
methodsThis retrospective study included data from 715 non-small cell lung cancer patients who were diagnosed pathologically at our center between 2018 and 2024. The dataset comprised demographic characteristics, tumor features, and treatment-related information. Propensity score matching was employed to adjust for baseline imbalances between male and female groups. Prognostic differences based on gender were assessed using Kaplan-Meier survival analysis, log-rank tests, and multivariate Cox regression models, with additional subgroup analysis.
resultsFollowing propensity score matching, the median survival for male patients was 23 months, while female patients had a median survival of 29 months. The mortality risk for males was 29.2% higher compared to females (HR = 1.292, 95% CI 1.003-1.664, P = 0.044). In the EGFR-TKI subgroup, the mortality risk for males was 49% higher than for females (HR = 1.490, 95% CI 1.035-2.145, P = 0.028), whereas no significant gender-related differences were observed in the immune checkpoint inhibitor subgroup. Multivariate Cox regression analysis further confirmed that male patients faced a significantly increased mortality risk compared to females (HR = 1.31, 95% CI 1.01-1.70, P = 0.046). Furthermore, AJCC T stage, N stage, and M stage were identified as independent prognostic factors. Chemotherapy and anti-angiogenesis therapy were associated with a reduced mortality risk. Subgroup analysis revealed that male patients had significantly worse prognoses than female patients, particularly among those with early lymph node metastasis (N0-1), no distant metastasis (M0), no brain metastasis, and those who underwent surgery.
conclusionGender is an independent prognostic factor in NSCLC. Male patients generally experience shorter overall survival compared to female patients, particularly in those receiving EGFR-TKI therapy and in certain clinical stages. Gender should be considered in clinical practice when making treatment decisions. Future multicenter prospective studies are needed to further validate these findings and explore the underlying biological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.